Overview

Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy

Status:
Completed
Trial end date:
2020-06-29
Target enrollment:
Participant gender:
Summary
Primary Objective: To test the hypothesis that basal insulin based treatment (G+) is noninferior to twice-daily premixed insulin (PM-2) in term of hemoglobin A1c (glycosylated hemoglobin, HbA1c) reduction from baseline to end of study. The test for superiority can be done if noninferiority is achieved. Secondary Objectives: - To assess efficacy in terms of percentage of patients achieving HbA1c <7% and HbA1c <7% without hypoglycemia. - To assess efficacy in terms of percentage of patients achieving fasting plasma glucose (FPG) <7 mmol/L and FPG <7 mmol/L without hypoglycemia. - To assess safety in term of occurrence of moderate/severe hypoglycemia. - To assess daily blood glucose (BG) variation. - To assess patient satisfaction.
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
Acarbose
Biphasic Insulins
Insulin
Insulin Aspart
Insulin aspart, insulin aspart protamine drug combination 30:70
Insulin Glargine
Insulin glulisine
Insulin, Globin Zinc
Insulin, Isophane
Metformin
Repaglinide